Source: SanBio Inc.
Date: March 20, 2012
Summary:
SanBio Inc. today announced the successful enrollment of the first dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, a cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 6 patients, of a total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been reported. Details of this clinical trial can be found here.
